HRT Financial LLC acquired a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,381 shares of the company’s stock, valued at approximately $296,000.
Several other hedge funds have also recently bought and sold shares of CRSP. Resources Investment Advisors Inc. bought a new position in shares of Crispr Therapeutics during the 4th quarter valued at $43,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Crispr Therapeutics by 96.7% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,627 shares of the company’s stock valued at $46,000 after acquiring an additional 800 shares in the last quarter. We Are One Seven LLC bought a new position in Crispr Therapeutics in the fourth quarter worth approximately $57,000. Flagship Harbor Advisors LLC grew its holdings in Crispr Therapeutics by 918.4% in the fourth quarter. Flagship Harbor Advisors LLC now owns 2,709 shares of the company’s stock worth $77,000 after purchasing an additional 2,443 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Crispr Therapeutics by 79.4% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,987 shares of the company’s stock worth $112,000 after purchasing an additional 1,765 shares during the last quarter. Hedge funds and other institutional investors own 42.24% of the company’s stock.
A number of research analysts have weighed in on CRSP shares. BidaskClub downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, December 20th. SunTrust Banks reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, December 31st. Zacks Investment Research raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a report on Thursday, January 3rd. Citigroup downgraded shares of Crispr Therapeutics from a “neutral” rating to a “sell” rating and lowered their target price for the company from $28.00 to $21.00 in a report on Tuesday, January 22nd. Finally, Goldman Sachs Group downgraded shares of Crispr Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $78.00 to $40.00 in a research note on Monday, January 28th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $45.75.
CRSP traded down $0.76 on Monday, reaching $37.15. The company had a trading volume of 317,037 shares, compared to its average volume of 750,954. Crispr Therapeutics AG has a one year low of $22.22 and a one year high of $73.90. The firm has a market capitalization of $1.99 billion, a PE ratio of -10.80 and a beta of 3.11.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, February 25th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $1.56 million. Crispr Therapeutics had a negative net margin of 5,281.08% and a negative return on equity of 48.35%. The firm’s revenue was down 99.7% compared to the same quarter last year. As a group, research analysts anticipate that Crispr Therapeutics AG will post -3.43 earnings per share for the current fiscal year.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Further Reading: Growth Stocks
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.